about
Trabectedin for the management of soft-tissue sarcoma.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.Perfusion characterization of liver metastases from endocrine tumors: Computed tomography perfusion.Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers.New treatment strategies in advanced neuroendocrine tumours.Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.Sunitinib achieved fast and sustained control of VIPoma symptoms.Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors.Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study.Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study.Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?Sorafenib-induced bilateral osteonecrosis of femoral heads.Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
P50
Q33384836-4C7B4C1B-379E-45B1-9366-EDC4AE8E768FQ34163515-21719D63-5BF1-4A8E-9244-F3401A32708BQ34427108-B24BBEB0-CB6D-4A6B-9033-171988F0AEFAQ34965132-79B620CB-F1B4-4050-BBE2-2BA6BA604BDDQ35081993-4450815E-FDF1-4A9B-90B0-976951A58932Q37578830-125A65E9-01B1-491C-BAE1-0565AD8A528DQ37943618-860DEAFE-1693-4B57-91EC-B1727CDE5F79Q38701102-E38D93CA-2A89-4FC9-B143-63EF2EFB4DD0Q39176092-0134A203-7C7E-432D-A1DC-8CDA1F16E38FQ39199931-693CF59A-7332-4D86-89C8-2A982611E421Q39372287-77796673-68F7-4604-8797-8C1B49F0FC14Q39398064-CFB218BC-19B8-4C51-B27D-24969C275228Q39638963-85232E59-1C03-4B9F-84F9-1DB922A14C1CQ39733256-61D93428-5C5F-4782-AF2B-B4C651F68525Q40853524-17DD6FD0-4EE2-4F41-A0F1-52D27B27B9CDQ40928663-B3AFC110-BDDE-4393-8091-9B0506A8C76DQ41981954-3A2653E0-C933-4AF7-9D0C-1F0368370401Q42699372-81104A98-479A-4E4D-849E-38FEEF44B04AQ42870246-D2F4A655-ED47-4A11-844C-F7D13898ACB6Q43102255-E664BCAE-077B-4CFD-A112-3A70AAA0DA25Q43193965-E6E688AA-6307-46CC-8E69-64A059C323F5Q43250047-88C69F76-9841-4D2E-81F1-9F455ACA0535Q43357159-291A87FE-EB11-4373-8793-874888722927
P50
description
onderzoeker
@nl
name
Catherine Lombard-Bohas
@ast
Catherine Lombard-Bohas
@en
Catherine Lombard-Bohas
@es
Catherine Lombard-Bohas
@sl
type
label
Catherine Lombard-Bohas
@ast
Catherine Lombard-Bohas
@en
Catherine Lombard-Bohas
@es
Catherine Lombard-Bohas
@sl
prefLabel
Catherine Lombard-Bohas
@ast
Catherine Lombard-Bohas
@en
Catherine Lombard-Bohas
@es
Catherine Lombard-Bohas
@sl